Advanced prostate adenocarcinoma
Clinical trials for Advanced prostate adenocarcinoma explained in plain language.
Never miss a new study
Get alerted when new Advanced prostate adenocarcinoma trials appear
Sign up with your email to follow new studies for Advanced prostate adenocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread
Disease control Recruiting nowThis phase II trial tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy, with or without additional hormone-blocking pills, can better control low-volume metastatic hormone-sensitive prostate cancer. The study enrolls men whose cancer has s…
Matched conditions: ADVANCED PROSTATE ADENOCARCINOMA
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage study tests a new treatment called ETB-DualNK-01 for men with advanced prostate cancer that has stopped responding to hormone therapy. The treatment uses donor immune cells (NK cells) that are engineered to target two cancer markers, PSMA and PSCA. The study aims…
Matched conditions: ADVANCED PROSTATE ADENOCARCINOMA
Phase 1 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Which prostate cancer drug is easier on patients? new trial aims to find out
Symptom relief Recruiting nowThis phase II trial compares the side effects of two standard treatments for advanced prostate cancer: abiraterone plus prednisone versus darolutamide alone. Researchers will track how many patients experience severe side effects (grade 3 or higher) over the course of treatment. …
Matched conditions: ADVANCED PROSTATE ADENOCARCINOMA
Phase 2 • Sponsor: University of California, Davis • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC